Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02195700 · ClinicalTrials.gov registry record · Phase 2
Aim to Reduce Movements in Tardive Dyskinesia
A Phase 2 study, sponsored by Auspex Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 117
- Enrollment target
NCT02195700 is a Phase 2 study that has completed, run by Auspex Pharmaceuticals. The registered enrollment target is 117 participants.
The verdict
NCT02195700, a Phase 2 study, has completed, sponsored by Auspex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 117 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
Interventions
- DRUG Placebo
- DRUG SD-809
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02195700
The ClinicalTrials.gov registry entry for NCT02195700 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Auspex Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02195700 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02195700 about?
NCT02195700 is a clinical study titled "Aim to Reduce Movements in Tardive Dyskinesia". The purpose of this study is to determine whether an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
What is the current status of trial NCT02195700?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 117 participants. The study started on 2014-06. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02195700?
The interventions under investigation include: Placebo (DRUG), SD-809 (DRUG).
Who is sponsoring clinical trial NCT02195700?
This trial is sponsored by Auspex Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.